Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
GSK announced that the European Commission has expanded the approval for Jemperli (dostarlimab) combined with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This expansion specifically includes those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors, significantly broadening treatment options for around 75% of endometrial cancer cases. This approval came following the RUBY Part 1 trial, which demonstrated a substantial improvement in overall survival rates compared to chemotherapy alone, marking a significant advancement in the treatment landscape for endometrial cancer.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company specializing in the development of pharmaceuticals, vaccines, and consumer healthcare products. The company is focused on advancing treatments in oncology, particularly through immuno-oncology and tumor-cell targeting therapies.
YTD Price Performance: 0.93%
Average Trading Volume: 7,971,149
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £55.45B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.
